GlassScriptPhysician profile
Tayler Devon Moser
NPI 1497463731
$944.05
in general payments reported to CMS, 2019-2025
18 companies · $201 in 2025
The $201 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $292 · 2024: $451 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $944.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $145.43 | 2023-2025 | Bexsero, Shingrix, Arexvy |
| Abbvie INC. | $134.48 | 2023-2025 | |
| Novo Nordisk INC | $129.37 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $97.45 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $83.02 | 2023-2025 | Mounjaro |
| Pfizer INC. | $49.66 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $46.30 | 2024-2025 | Airsupra, Farxiga |
| Amgen INC. | $41.81 | 2024-2025 | Repatha, Repatha, Otezla |
| Kyowa Kirin, INC. | $28.69 | 2024 | Crysvita |
| Shield Therapeutics INC | $28.46 | 2023 | Accrufer |
| Merck Sharp & Dohme LLC | $28.32 | 2023-2024 | M-M-R II, Gardasil 9, Vaxneuvance |
| Cequr Corporation | $26.50 | 2024 | Cequr Simplicity |
| Alkermes, INC. | $21.32 | 2025 | Vivitrol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.45 | 2024 | Synjardy, Jardiance |
| Indivior INC. | $18.33 | 2024 | Sublocade |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $17.11 | 2023 | Glassia |
| Medtronic, INC. | $13.79 | 2023 | Minimed 780g |
| Braeburn INC. | $13.56 | 2025 | Brixadi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tayler Moser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.